Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy

Nobelpharma has just announced the FDA approval of sirolimus .2% gel (called Hyftor). It is now the first approved, topical therapy for facial angiofibroma associated with the rare condition tuberous…

Continue Reading Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy
New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics
source: pixabay.com

New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics

  AI Therapeutics is a biopharmaceutical company that has created an artificial intelligence platform that is meant to match drugs to new indications. This platform, called Guardian Angel, has matched…

Continue Reading New Therapies for LAM Disease and Facial Angiofibroma from AI Therapeutics